Application No.: 10/570,046 Filing Date: April 17, 2006

AMENDMENTS TO THE CLAIMS

1.-27 (Cancelled).

28. (Currently Amended) A method for promoting granulation formation and enhanced wound healing in enclosure of a skin ulcer of a mammal comprising:

selecting a mammal having a skin ulcer to receive a drug that promotes granulation formation and enhanced wound healing in said skin ulcer; and

treating a mammal having a skin ulcer with a therapeutically effective amount of a drug comprising topically administering a drug that comprises a protein of the sequence of SEQ ID NO: 1, wherein said drug is administered to said skin ulcer of said mammal topically. to said skin ulcer in an amount that promotes granulation formation and enhanced wound healing.

- 29. (Cancelled).
- 30. (Cancelled).
- 31. (Previously Presented) The method of claim 28, wherein said drug further comprises an antiseptic.
- 32. (Previously Presented) The method of claim 28, wherein said drug further comprises a fatty acid ester.
- 33. (Previously Presented) The method of claim 28, wherein said drug is in the form of a ointment.
- 34. **(Previously Presented)** The method of claim 28, wherein said drug is in the form of a cream.
- 35. (Previously Presented) The method of claim 28, wherein said drug is in the form of a gel.

Application No.:

10/570,046

Filing Date:

April 17, 2006

36. (Previously Presented) The method of claim 28, wherein said drug is in the form of a liquid.

37-44. (Cancelled).

45. (Currently Amended) A method for promoting granulation formation and enhanced wound healing in enclosure of a skin ulcer of a mammal comprising:

selecting a mammal having a skin ulcer to receive a drug that promotes granulation formation and enhanced wound healing in said skin ulcer;

treating a mammal having a skin ulcer with a therapeutically effective amount of a drug that comprises a protein of the sequence of SEQ ID NO: 1, wherein said drug is administered to said skin ulcer of said mammal topically;

providing a <u>sealing-type</u> wound covering agent selected from the group consisting of a hydrocolloid dressing material, a hydrogen dressing material, a polyurethane dressing material, a hydrofiber dressing material, and a polyurethane foam; <u>and</u>

contacting the skin ulcer of said mammal with said wound covering agent.

topically administering a drug that comprises a protein of the sequence of SEQ ID NO: 1 to said skin ulcer in an amount that promotes granulation formation and enhanced wound healing; and

analyzing the formation of granulation tissue and wound healing at the skin ulcer of said mammal.

46. (Cancelled).

- 47. (Previously Presented) The method of claim 45, wherein said drug further comprises an antiseptic.
- 48. (Previously Presented) The method of claim 45, wherein said drug further comprises a fatty acid ester.

Application No.:

10/570,046

Filing Date:

April 17, 2006

49. (Previously Presented) The method of claim 45, wherein said drug is in the form of a ointment.

50. (**Previously Presented**) The method of claim 45, wherein said drug is in the form of a cream.

51. (Previously Presented) The method of claim 45, wherein said drug is in the form of a gel.

52. **(Previously Presented)** The method of claim 45, wherein said drug is in the form of a liquid.

53. (New) A method for promoting granulation formation and enhanced enclosure of a skin ulcer of a mammal comprising:

treating a mammal having a skin ulcer with a therapeutically effective amount of a drug that comprises HGF produced from a gene encoding a peptide consisting of the amino acid sequence of SEQ. ID. NO.: 1, wherein said drug is administered to said skin ulcer of said mammal topically.

54. (New) A method for promoting granulation formation and enhanced enclosure of a skin ulcer of a mammal comprising:

treating a mammal having a skin ulcer with a therapeutically effective amount of a drug that comprises HGF produced from a gene encoding a peptide consisting of the amino acid sequence of SEQ. ID. NO.: 1, wherein said drug is administered to said skin ulcer of said mammal topically;

providing a sealing-type wound covering agent selected from the group consisting of a hydrocolloid dressing material, a hydrogen dressing material, a polyurethane dressing material, a hydropolymer dressing material, a hydrofiber dressing material, and a polyurethane foam; and

contacting the skin ulcer of said mammal with said wound covering agent.